Showing 3961-3970 of 10219 results for "".
Take 5
https://practicaldermatology.com/columns/take-5/pd1008_15-pdf/22639/Take 5
https://practicaldermatology.com/columns/take-5/PD0908take5-pdf/22649/Take 5
https://practicaldermatology.com/columns/take-5/PD0708take5-pdf/22663/Take 5
https://practicaldermatology.com/columns/take-5/PD0608Take5-pdf/22678/Take 5
https://practicaldermatology.com/columns/take-5/PD0508Take5-pdf/22691/Coding Checklist
https://practicaldermatology.com/topics/general-topics/PD1105Coding-pdf/22111/- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product
- Consensus Paper Addresses S. aureus Exacerbated ADhttps://practicaldermatology.com/news/consensus-paper-addresses-s-aureus-exacerbated-ad/2468445/A significant unmet need exists for a single topical atopic dermatitis (AD) therapy effective against all symptoms—including pruritis, S. aureus-driven AD exacerbation, infection, and inflammation—across AD severity levels, according to a panel of six pediatric dermatologists who participated in
- Allergan Vet Julian S. Gangolli Joins Revance's Board of Directorshttps://practicaldermatology.com/news/allergan-vet-julian-s-gangolli-joins-revances-board-of-directors/2458508/Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, is now on Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016. He will help Revance progress toward regulatory approv
- Leo Pharma's Adbry Reduces S. aureus Skin Colonization in Kids With ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-reduces-s-aureus-skin-colonization-in-kids-with-ad/2461616/Leo Pharma’s Adbry (tralokinumab-ldrm) significantly reduced the abundance of Staphylococcus aureus in the lesional and non-lesional skin of adolescents with atopic dermatitis (AD) after 16 weeks, according to new data presented at the American Academy of Dermatology